Rochefort

Philadelphia-negative myeloproliferative neoplasms MPNs such as Polycythemia Vera, Essential Thrombocythemia, and Prefibrotic Myelofibrosis are chronic blood cancers caused by mutations affecting blood cell growth. These diseases carry a high risk of blood clots, which can cause serious complications and death. Current treatments include low-dose aspirin, but blood clots still occur in some patients despite therapy. This trial aims to study whether direct oral anticoagulants DOACs, which have shown benefits in other cancer patients, might help prevent blood clots in MPN patients with a specific mutation called JAK2V617F. Participants will be randomly assigned to receive either a direct oral anticoagulanteither Apixaban 2.5 mg twice daily or Rivaroxaban 10 mg once dailyor low-dose aspirin 100 mg once daily. The choice of DOAC is up to the investigator. The treatments will be given to high-risk patients for up to 24 months to compare their effects on clot prevention. Throughout the study, participants will be closely monitored for any thrombotic or bleeding events. During the trial, researchers will track the time until any arterial or venous blood clots occur, as well as any major or clinically relevant bleeding events. They will also evaluate survival, adherence to therapy, quality of life, and healthcare costs related to these treatments. Participants will have regular follow-ups over 24 months, including assessments for heart rhythm problems and safety monitoring. This comprehensive approach aims to better understand the benefits and risks of DOACs compared to aspirin in preventing clots in MPN patients.

Researchers are creating the largest possible real-life group of patients with Chronic Myeloid Leukemia CML to collect long-term follow-up data. This observational study aims to analyze epidemiological trends, identify patient subgroups based on treatment response, evaluate new medications used in everyday care, study treatment discontinuations, and assess the effects of evolving treatment recommendations. The study collects clinical and biological information from CML patients both prospectively and retrospectively starting from diagnosis. Data gathering continues throughout the long-term follow-up period, even after treatment has stopped. There are no specific drugs or interventions administered in this observational study it focuses on monitoring and recording real-world patient experiences and responses. Participants provide data throughout their disease course, which may be collected for up to 30 years or until death or last follow-up. Researchers evaluate multiple outcomes including molecular and cytogenetic responses, treatment efficacy and tolerance, prognosis scores at diagnosis, body measurements, and medical history related to CML. This extensive monitoring helps better understand CML progression and treatment in real-life settings.

The Dataids cohort is a large, ongoing observational study following over 30,000 HIV-infected patients receiving care at more than 15 HIV centers across France. The study aims to monitor clinical practice, changes in the course of HIV infection and related co-infections or co-morbidities, and assess factors influencing the clinical, immunological, and virological outcomes of HIV. It also evaluates the effectiveness of antiretroviral therapy ART and outcomes related to hepatitis C virus HCV treatment. Patients enrolled in the cohort are followed during routine outpatient visits, regardless of their CD4 cell count, HIV viral load, or ART status. Data collected annually include demographic information, immunological and virological measures, serological tests for hepatitis B, hepatitis C, and syphilis, as well as laboratory, therapeutic, and clinical data. This long-term study has been enrolling patients since 2010 and continues to collect data prospectively. Participants provide data through their scheduled clinic visits, and researchers track outcomes such as the proportion of patients with undetectable HIV viral load, ART usage patterns, HCV treatment uptake and success, CD4 cell counts, and incidence of HIV-related events. The main outcome measured is the proportion of treated patients with HIV plasma viral load below 50 copiesmL, averaged over six months. The study extends through 2030, with ongoing annual monitoring and data collection as part of routine care.